ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
Sheng-Li Lin, Li-Ying Yan, Xin-Tian Zhang et al. · 2010
Read ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways by Sheng-Li Lin, Li-Ying Yan, Xin-Tian Zhang et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0009013.txt.
Description
Sheng-Li Lin and co-authors traced how a hormone receptor variant can flip a cancer drug's effect, in PLOS ONE in 2010. Tamoxifen usually blocks estrogen action in hormone-sensitive cancers. A newer receptor variant, ER-alpha36, lacks the usual gene-switching parts. It works instead through fast signals at the cell surface.
In endometrial cancer cells, this variant made tamoxifen act like estrogen instead. It fired two growth pathways, MAPK/ERK and PI3K/Akt, in response to the drug. A blocker becoming a trigger helps explain tamoxifen resistance. Tumours carrying the variant may need a different treatment plan.
Catalog record
| CREATOR | Sheng-Li Lin, Li-Ying Yan, Xin-Tian Zhang et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009013